I believe once the phase 2 long hauler data is com

I believe once the phase 2 long hauler data is completely evaluated you will see a BP partner step in to fund the next trial as well as lock in licensing/selling rights to Vyrologix for Long Haulers. Although I don’t expect revenue for LH to start until mid next year if phase 3 is successful, the licensing rights alone are with a very large sum of money and the investment in the trial will allow Cytodyn to hold back on more investments in any covid related trial..if what I mentioned here holds true, I would expect the SP to move up to at least the 5 to 7 dollar a share level after the BP announcement.
There may be truth to the rumor regarding the University of Nebraska based on the fact the cancer research in the medical school is named after buffet’s cousin who died of cancer back in the 1990’s . I wouldn’t doubt if that school gets a perpetual donation from Buffet. Tie that into Dr Kelly’s comment about major academic institutions that will give Cytodyn credibility’s and it makes sense. Doesn’t say it’s true but the University of Nebraska is a top 10 medical school in the country.